Abstract: The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formulae (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing viruses, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: Architecture for enhancing the compression (e.g., luma, chroma) of a video signal and improving the perceptual quality of the video compression schemes. The architecture operates to reshape the normal multimodal energy distribution of the input video signal to a new energy distribution. In the context of luma, the algorithm maps the black and white (or contrast) information of a picture to a new energy distribution. For example, the contrast can be enhanced in the middle range of the luma spectrum, thereby improving the contrast between a light foreground object and a dark background. At the same time, the algorithm reduces the bit-rate requirements at a particular quantization step size. The algorithm can be utilized also in post-processing to improve the quality of decoded video.

Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: The present invention discloses compounds of Formulae (I) and (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

Abstract: Techniques and tools are described for parameterization, signaling and use of in-loop filtering control information for interlaced video frames in video acceleration. For example, for a macroblock of an interlaced video frame, a decoder parameterizes in-loop filtering decisions as filter control information for video acceleration. The control information indicates filtering control decisions for external edges and internal edges of luma blocks and chroma blocks of the macroblock. The decoder makes the control information available to a video accelerator. The video accelerator retrieves the in-loop filtering control information. For a macroblock of an interlaced video frame, the video accelerator then performs in-loop filtering based at least in part on the control information.

Abstract: A video encoder/decoder utilizes a bistream syntax that provides an independently decodable, partial picture unit, which may be in the form of a unit containing one or more contiguous rows of macroblocks (called a slice). This slice layer provides a flexible combination of error-resilience and compression efficiency. The slice layer encodes an efficient addressing mechanism (e.g., a syntax element specifying a beginning macroblock row of the slice layer), as well as an efficient mechanism to optionally retransmit picture header information. The slice layer provides decoding and reconstruction independence by disabling all forms of prediction, overlap and loop-filtering across slice-boundaries. This permits a slice coded in intra-mode to be reconstructed error-free, irrespective of errors in other regions of the picture.

Abstract: A video encoder/decoder utilizes a bistream syntax that provides an independently decodable, partial picture unit, which may be in the form of a unit containing one or more contiguous rows of macroblocks (called a slice). This slice layer provides a flexible combination of error-resilience and compression efficiency. The slice layer encodes an efficient addressing mechanism (e.g., a syntax element specifying a beginning macroblock row of the slice layer), as well as an efficient mechanism to optionally retransmit picture header information. The slice layer provides decoding and reconstruction independence by disabling all forms of prediction, overlap and loop-filtering across slice-boundaries. This permits a slice coded in intra-mode to be reconstructed error-free, irrespective of errors in other regions of the picture.